NASDAQ:BIOC - Biocept Stock Price, Price Target & More

$0.24 0.00 (0.00 %)
(As of 04/23/2018 03:24 PM ET)
Previous Close$0.24
Today's Range$0.23 - $0.25
52-Week Range$0.23 - $1.90
Volume754,623 shs
Average Volume2.43 million shs
Market Capitalization$16.57 million
P/E Ratio-0.32
Dividend YieldN/A
Beta1.77

About Biocept (NASDAQ:BIOC)

Biocept logoBiocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Debt-to-Equity Ratio0.89%
Current Ratio0.91%
Quick Ratio0.81%

Price-To-Earnings

Trailing P/E Ratio-0.32
Forward P/E Ratio-0.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.07 million
Price / Sales3.22
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book12.00

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-21,610,000.00
Net Margins-426.48%
Return on Equity-374.92%
Return on Assets-169.29%

Miscellaneous

Employees95
Outstanding Shares68,040,000

How to Become a New Pot Stock Millionaire

Biocept (NASDAQ:BIOC) Frequently Asked Questions

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept (NASDAQ:BIOC) issued its earnings results on Wednesday, March, 28th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The medical research company earned $1 million during the quarter, compared to analysts' expectations of $1.23 million. Biocept had a negative net margin of 426.48% and a negative return on equity of 374.92%. View Biocept's Earnings History.

When is Biocept's next earnings date?

Biocept is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Biocept.

What price target have analysts set for BIOC?

2 equities research analysts have issued twelve-month target prices for Biocept's shares. Their predictions range from $1.00 to $1.50. On average, they anticipate Biocept's share price to reach $1.25 in the next year. View Analyst Ratings for Biocept.

Who are some of Biocept's key competitors?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 55)
  • Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)
  • Dr. Veena M. Singh, Sr. VP, Sr. Medical Director & Member of Scientific Advisory Board (Age 43)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations, Sec. & Principal Accounting Officer (Age 60)

Has Biocept been receiving favorable news coverage?

Headlines about BIOC stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biocept earned a news sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 44.73 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.24.

How big of a company is Biocept?

Biocept has a market capitalization of $16.57 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Biocept employs 95 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


MarketBeat Community Rating for Biocept (BIOC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biocept (NASDAQ:BIOC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. Their average twelve-month price target is $1.25, suggesting that the stock has a possible upside of 420.83%. The high price target for BIOC is $1.50 and the low price target for BIOC is $1.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.25$1.50$2.25$2.50
Price Target Upside: 420.83% upside134.38% upside251.56% upside78.57% upside

Biocept (NASDAQ:BIOC) Consensus Price Target History

Price Target History for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ:BIOC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018Westpark CapitalReiterated RatingOutperform$1.00MediumView Rating Details
11/14/2017Chardan CapitalReiterated RatingBuy -> Buy$2.50 -> $1.50N/AView Rating Details
3/13/2017Roth CapitalReiterated RatingBuy$1.60 -> $3.00LowView Rating Details
11/10/2016Feltl & Co.UpgradeHold -> Buy$2.00N/AView Rating Details
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Biocept (NASDAQ:BIOC) Earnings History and Estimates Chart

Earnings by Quarter for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ:BIOC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.28 EPS
Next Year EPS Consensus Estimate: $-0.22 EPS

Biocept (NASDAQ BIOC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.10)N/AView Earnings Details
3/28/2018Q4 2017($0.16)($0.18)$1.23 million$1.00 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.19)($0.20)$1.39 million$1.11 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.21)$1.23 million$1.28 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.22)($0.21)$1.32 million$1.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.34)($0.2680)$1.26 million$1.29 millionViewListenView Earnings Details
11/9/2016Q316($0.57)($0.57)$0.76 million$1.05 millionViewListenView Earnings Details
8/2/2016Q216($0.22)($0.20)$0.37 million$0.66 millionViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)$0.48 million$0.22 millionViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$0.78 million$0.17 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)$0.30 million$0.15 millionViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)$0.30 million$0.08 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.82)($0.87)$0.40 million$0.01 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.67)($0.67)$0.10 million$0.02 millionViewN/AView Earnings Details
5/14/2014Q1 2014($5.88)$0.03 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biocept (NASDAQ:BIOC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biocept (NASDAQ BIOC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 8.68%
Insider Trading History for Biocept (NASDAQ:BIOC)
Institutional Ownership by Quarter for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ BIOC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/19/2016Claire ReissMajor ShareholderBuy227,272$1.10$249,999.20View SEC Filing  
10/19/2016David F. HaleDirectorBuy90,909$1.10$99,999.90View SEC Filing  
10/19/2016Lyle J. ArnoldSVPBuy45,000$1.10$49,500.00View SEC Filing  
10/19/2016Timothy KennedyCFOBuy36,363$1.10$39,999.30View SEC Filing  
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.0058,985View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biocept (NASDAQ BIOC) News Headlines

Source:
DateHeadline
Critical Survey: Biocept (BIOC) and Genomic Health (GHDX)Critical Survey: Biocept (BIOC) and Genomic Health (GHDX)
www.americanbankingnews.com - April 21 at 7:36 PM
Biocept (BIOC) and Its Competitors Critical AnalysisBiocept (BIOC) and Its Competitors Critical Analysis
www.americanbankingnews.com - April 21 at 9:18 AM
Reviewing Biocept (BIOC) and Its CompetitorsReviewing Biocept (BIOC) and Its Competitors
www.americanbankingnews.com - April 21 at 9:18 AM
Biocept (BIOC) Downgraded by Zacks Investment ResearchBiocept (BIOC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:30 PM
Biocept (BIOC) Upgraded by Zacks Investment Research to "Buy"Biocept (BIOC) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 17 at 7:34 PM
Critical Comparison: Biocept (BIOC) versus The CompetitionCritical Comparison: Biocept (BIOC) versus The Competition
www.americanbankingnews.com - April 15 at 5:15 PM
Miragen Therapeutics (MGEN) and Biocept (BIOC) Head to Head SurveyMiragen Therapeutics (MGEN) and Biocept (BIOC) Head to Head Survey
www.americanbankingnews.com - April 12 at 11:19 PM
Westpark Capital Reaffirms Outperform Rating for Biocept (BIOC)Westpark Capital Reaffirms Outperform Rating for Biocept (BIOC)
www.americanbankingnews.com - April 12 at 9:35 PM
Comparing Biocept (BIOC) & Its CompetitorsComparing Biocept (BIOC) & Its Competitors
www.americanbankingnews.com - April 12 at 5:27 PM
Zacks: Analysts Expect Biocept (BIOC) to Announce -$0.07 EPSZacks: Analysts Expect Biocept (BIOC) to Announce -$0.07 EPS
www.americanbankingnews.com - April 8 at 7:28 AM
Biocept to Webcast Presentation at the 7th Annual MicroCap ConferenceBiocept to Webcast Presentation at the 7th Annual MicroCap Conference
finance.yahoo.com - April 6 at 8:18 AM
Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%
finance.yahoo.com - April 6 at 8:18 AM
Biocept (BIOC) vs. The Competition Head to Head ContrastBiocept (BIOC) vs. The Competition Head to Head Contrast
www.americanbankingnews.com - April 5 at 3:03 PM
Biocept (BIOC) Given "Outperform" Rating at Westpark CapitalBiocept (BIOC) Given "Outperform" Rating at Westpark Capital
www.americanbankingnews.com - April 4 at 11:55 AM
Critical Contrast: Biocept (BIOC) & Its RivalsCritical Contrast: Biocept (BIOC) & Its Rivals
www.americanbankingnews.com - April 4 at 5:15 AM
Contrasting Biocept (BIOC) and Its CompetitorsContrasting Biocept (BIOC) and Its Competitors
www.americanbankingnews.com - April 3 at 1:26 PM
Biocept to Present at the 7th Annual MicroCap ConferenceBiocept to Present at the 7th Annual MicroCap Conference
finance.yahoo.com - April 3 at 8:15 AM
Biocepts (BIOC) CEO Michael Nall on Q4 2017 Results - Earnings Call TranscriptBiocept's (BIOC) CEO Michael Nall on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 29 at 8:19 AM
Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in ChinaBiocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China
finance.yahoo.com - March 29 at 8:19 AM
Biocept (BIOC) Posts  Earnings Results, Misses Expectations By $0.02 EPSBiocept (BIOC) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - March 29 at 7:38 AM
Biocept Reports 2017 Fourth Quarter and Full Year Financial ResultsBiocept Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 28 at 5:24 PM
Biocept (BIOC), Thermo Fisher Scientific Enter into Technology and Commercial CollaborationBiocept (BIOC), Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
www.streetinsider.com - March 28 at 8:22 AM
BRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial CollaborationBRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration
www.reuters.com - March 28 at 8:22 AM
Biocept and Thermo Fisher Scientific Enter into Technology and Commercial CollaborationBiocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
finance.yahoo.com - March 28 at 8:22 AM
Comparing Biocept (BIOC) & Kindred Healthcare (KND)Comparing Biocept (BIOC) & Kindred Healthcare (KND)
www.americanbankingnews.com - March 24 at 1:18 AM
OmniComm Systems (OMCM) and Biocept (BIOC) Critical AnalysisOmniComm Systems (OMCM) and Biocept (BIOC) Critical Analysis
www.americanbankingnews.com - March 22 at 1:38 PM
Biocept to Present Recent Advances in Biomarker Identification from ... - PR Newswire (press release)Biocept to Present Recent Advances in Biomarker Identification from ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:41 AM
Biocept (BIOC) Set to Announce Quarterly Earnings on WednesdayBiocept (BIOC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:56 AM
Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbios 11th Biomarker SummitBiocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit
finance.yahoo.com - March 20 at 8:20 AM
Head to Head Comparison: Biocept (BIOC) vs. Streamline Health Solutions (STRM)Head to Head Comparison: Biocept (BIOC) vs. Streamline Health Solutions (STRM)
www.americanbankingnews.com - March 17 at 5:14 PM
Biocepts Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer ... - PR Newswire (press release)Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer ... - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:13 AM
Biocepts Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual MeetingBiocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 15 at 8:10 AM
Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March ... - PR Newswire (press release)Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 8:29 AM
Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018
finance.yahoo.com - March 12 at 8:29 AM
Biocept to Present at the 30th Annual ROTH ConferenceBiocept to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 5:44 PM
Short Interest in Biocept Inc (BIOC) Increases By 52.8%Short Interest in Biocept Inc (BIOC) Increases By 52.8%
www.americanbankingnews.com - March 3 at 3:26 AM
Biocept (BIOC) to Release Quarterly Earnings on MondayBiocept (BIOC) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - February 26 at 3:20 AM
Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector PlatformBiocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
finance.yahoo.com - February 5 at 8:58 AM
Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.
finance.yahoo.com - February 1 at 9:10 AM
Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung CancerBiocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
finance.yahoo.com - January 30 at 8:47 AM
Technical Perspectives on Medical Research Stocks -- Accelerate Diagnostics, Biocept, Exact Sciences, and HTG Molecular DiagnosticsTechnical Perspectives on Medical Research Stocks -- Accelerate Diagnostics, Biocept, Exact Sciences, and HTG Molecular Diagnostics
www.bizjournals.com - January 29 at 9:10 AM
Biocept Announces Pricing of $15.0 Million Public Offering of 33333333 Shares of Common Stock and Warrants to ... - PR Newswire (press release)Biocept Announces Pricing of $15.0 Million Public Offering of 33333333 Shares of Common Stock and Warrants to ... - PR Newswire (press release)
www.prnewswire.com - January 27 at 3:42 PM
Biocept Inc (BIOC) Dilutes Shareholders a Second Time in Two MonthsBiocept Inc (BIOC) Dilutes Shareholders a Second Time in Two Months
finance.yahoo.com - January 26 at 3:39 PM
BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and WarrantsBRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants
www.reuters.com - January 26 at 8:43 AM
Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common StockBiocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
finance.yahoo.com - January 26 at 8:43 AM
Zacks Investment Research Lowers Biocept (BIOC) to HoldZacks Investment Research Lowers Biocept (BIOC) to Hold
www.americanbankingnews.com - January 18 at 6:10 PM
Scientists seek super-shot for flu 100 years after pandemicScientists seek super-shot for flu 100 years after pandemic
finance.yahoo.com - January 17 at 3:38 PM
Biocept (BIOC) Rating Increased to Buy at Zacks Investment ResearchBiocept (BIOC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM
Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer BiomarkersBiocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
finance.yahoo.com - January 9 at 11:10 AM
Biocept Obtains Patent in Australia for its Molecular Biomarker ... - PR Newswire (press release)Biocept Obtains Patent in Australia for its Molecular Biomarker ... - PR Newswire (press release)
www.prnewswire.com - January 5 at 11:42 AM

SEC Filings

Biocept (NASDAQ:BIOC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biocept (NASDAQ:BIOC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biocept (NASDAQ BIOC) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.